Intervention not reported
The amount of bleeding ‐ not measured · patients with solid tumours with thrombocytopenia during chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Quality of life score ‐ not measured · patients with solid tumours with thrombocytopenia during chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Number of patients with at least one bleeding episode of any severity · patients with solid tumours without thrombocytopenia before chemotherapy
It is very uncertain whether the intervention changes number of patients with at least one bleeding episode of any severity (very low certainty).
1 finding from 1 review
Intervention not reported
Number of patients with at least one severe/life‐threatening bleeding episode · patients with solid tumours without thrombocytopenia before chemotherapy
It is very uncertain whether the intervention changes number of patients with at least one severe/life‐threatening… (very low certainty).
1 finding from 1 review
Intervention not reported
Number of treatment cycles with at least one bleeding episode ‐ not measured · patients with solid tumours without thrombocytopenia before chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Number of days on which bleeding occurred ‐ not measured · patients with solid tumours without thrombocytopenia before chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
The amount of bleeding ‐ not measured · patients with solid tumours without thrombocytopenia before chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Quality of life score ‐ not measured · patients with solid tumours without thrombocytopenia before chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Overall survival ‐ not measured · patients with solid tumours with thrombocytopenia during chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Number of patients with at least one bleeding episode of any severity · patients with solid tumours with thrombocytopenia during chemotherapy
It is very uncertain whether the intervention changes number of patients with at least one bleeding episode of any severity (very low certainty).
1 finding from 1 review
Number of participants with 'any bleeding' event(s) (WHO grade 1 to 4 or equivalent) ‐ · thrombocytopenia
Pathogen‐reduced platelets may leads to higher number of participants with 'any bleeding' event(s) (WHO grade 1 to… compared with standard platelets (low certainty).
1 finding from 1 review
Number of participants with clinically significant bleeding · thrombocytopenia
Pathogen‐reduced platelets showed no clear difference in number of participants with 'clinically significant' bleeding… compared with standard platelets (moderate certainty).
1 finding from 1 review
Number of participants with 'severe' bleeding event(s) (WHO grade ≥ 3 or equivalent) ‐ · thrombocytopenia
Pathogen‐reduced platelets showed no clear difference in number of participants with 'severe' bleeding event(s) (WHO grade ≥… compared with standard platelets (moderate certainty).
1 finding from 1 review
All‐cause mortality · thrombocytopenia
Pathogen‐reduced platelets showed no clear difference in all‐cause mortality compared with standard platelets (moderate certainty).
1 finding from 1 review
Number of participants with a serious adverse event · thrombocytopenia
Pathogen‐reduced platelets showed no clear difference in number of participants with a serious adverse event compared with standard platelets (moderate certainty).
1 finding from 1 review
Number of participants experiencing platelet refractoriness · thrombocytopenia
Pathogen‐reduced platelets leads to higher number of participants experiencing platelet refractoriness compared with standard platelets (high certainty).
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · thrombocytopenia
1 finding from 1 review
Overall survival · Adult patients with myelodysplastic syndromes and thrombocytopenia
1 finding from 1 review
Mortality during study · Adult patients with myelodysplastic syndromes and thrombocytopenia
Thrombopoietin mimetics showed no clear difference in mortality during study compared with placebo (low certainty).
1 finding from 1 review
Transformation to AML · Adult patients with myelodysplastic syndromes and thrombocytopenia
It is very uncertain whether thrombopoietin mimetics changes transformation to AML compared with placebo (very low certainty).
1 finding from 1 review